1. In Vivo
  2. >>ESG
  3. >>Diversity & Inclusion

All The Way To The Top: Diversity And Inclusion In Pharma Leadership

 
• By Peter Mansell

Policies, programs and strategies promoting diversity and inclusion are almost as ubiquitous in the pharmaceutical industry these days as environmental commitments. That reflects enormous cultural change over the last few generations, hastened in recent history by initiatives such as MeToo or Black Lives Matter.  

building blocks
• Source: Alamy

The challenge for companies today is to ensure their diversity and inclusion (D&I) efforts have real meaning, force and strategic weight. They must also show that D&I is not simply window-dressing or a defensive response to the cultural convulsions of recent years. That means embedding D&I sustainably in corporate values as not only the right but the rational and commercially astute thing to do.

D&I in leadership is where the rubber really hits the road. If pharmaceutical companies are serious about D&I, it needs to go all the way to the top. Ideally, diverse...

More from Diversity & Inclusion

RESILIENCE Initiative Navigates The World Of Making Medicines Through VR Technology

 
• By Anabel Costa-Ferreira

The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

 
• By Brian Yang

Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.

Infographic: Analyzing The Gap In Women’s Health Care

 
• By Anabel Costa-Ferreira

Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.

Growing Calls For Labelling Changes With Obesity Patients In Mind

 
• By Ed Silverman

Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.

More from ESG

Global Regulator Action To Improve Diversity In Clinical Trials

 
• By Vibha Sharma

As efforts to improve diversity in clinical trials gain momentum globally, regulators in the UK, the EU, Canada, Australia and Japan were asked about their efforts to support representative enrolment. 

Providing The Balance Between Medtech Innovation And Providers’ Sustainability

 
• By Ashley Yeo

Royal Philips is at the forefront of the driving environmental sustainability along the Scope 1-2-3 chain. The company hosted a round table in Amsterdam to hear experiences from providers.

FDA Publishes Updated Roadmap For Advancing Women’s Health

 
• By Brian Bossetta

The US FDA’s Office of Women’s Health provides a research roadmap to address health concerns specific to women. The FDA recently updated the roadmap, outlining areas in which further research is needed.